Where can I find news about MRK?

The latest headlines, third-party analysis, and SEC filings for Merck & Co., Inc. (MRK) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.

Where are MRK's SEC filings?

Merck & Co., Inc. (MRK)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.

Where are MRK's earnings call transcripts?

Full earnings call transcripts for Merck & Co., Inc. (MRK), with prepared remarks plus speaker-by-speaker analyst Q&A, live on the Earnings tab alongside the Earnings Reports section that links each quarter's press release and SEC report.

MRK

Merck & Co., Inc.

NYSE·Drug Manufacturers, General · Healthcare

$145.27$1.97−1.34%

Pre-market·$145.93+0.45%

Market cap$358.41B·Market closed·Oct 23 4:01 PM EDT

News & Analysis

Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29
Merck (NYSE:MRK | MRK Price Prediction) reports third-quarter results on Thursday, Oct. 29. KEYTRUDA still anchors the business, but I'll be watching whether newer launches are growing fast enough to cushion the drug's 2028 patent loss.
247wallst.comOct 25, 2026 · 11:31 AM
Merck & Co., Inc. $MRK Stock Sold by Carolina Wealth Advisors LLC
Carolina Wealth Advisors LLC cut its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 97.8% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 694 shares of the company's stock after selling 31,477 shares during the period. Carolina Wealth
defenseworld.netOct 25, 2026 · 4:49 AM
Merck & Co., Inc. $MRK Stock Position Increased by Fifth Third Wealth Advisors LLC
defenseworld.netOct 24, 2026 · 4:24 AM
AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?
When a drugmaker's top product loses patent protection, the dividend usually takes the hit.
247wallst.comOct 23, 2026 · 3:15 PM
Merck CEO on melanoma vaccine results: The prescribing community will find results quite meaningful
Merck CEO Rob Davis joins 'Squawk on the Street' to discuss leaked data of melanoma vaccine trials, the drop off the company's stock price and more.
youtube.comOct 23, 2026 · 12:06 PM
Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall
Beneath the chaos surrounding Moderna and Merck's latest data on their personalized cancer vaccine, oncologists see something else: an important milestone in melanoma treatment. The companies on Thursday released detailed results from a Phase 3 trial on their mRNA-based shot after partial data leaked on social media platforms earlier that day.
cnbc.comOct 23, 2026 · 11:24 AM
Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip
Full late-stage results for the personalized melanoma vaccine from Moderna (NASDAQ:MRNA | MRNA Price Prediction) and Merck (NYSE:MRK) came back positive, yet the selling hasn't stopped. Those numbers landed short of the loftiest hopes built into a long rally.
247wallst.comOct 23, 2026 · 9:17 AM
Merck & Co., Inc. $MRK Stock Position Increased by Brookstone Capital Management
defenseworld.netOct 23, 2026 · 3:45 AM

SEC Filings

25-NSE
Oct 15, 2026View on SEC
8-K
Oct 13, 2026View on SEC
10-Q
Aug 7, 2026View on SEC
13F-HR
Aug 7, 2026View on SEC
8-K
Aug 4, 2026View on SEC
11-K
Jun 24, 2026View on SEC

Frequently Asked Questions About MRK

Where can I find news about MRK?: The latest headlines, third-party analysis, and SEC filings for Merck & Co., Inc. (MRK) are listed on this page. Headlines come from across the financial press; filings come directly from SEC EDGAR.
Where are MRK's SEC filings?: Merck & Co., Inc. (MRK)'s 10-K (annual report), 10-Q (quarterly report), 8-K (current report), and proxy filings are listed in the SEC Filings section on this page with direct links to the official EDGAR copies.
Where are MRK's earnings call transcripts?: Full earnings call transcripts for Merck & Co., Inc. (MRK), with prepared remarks plus speaker-by-speaker analyst Q&A, live on the Earnings tab alongside the Earnings Reports section that links each quarter's press release and SEC report.

Merck & Co., Inc.

Frequently Asked Questions About MRK

Merck & Co., Inc.

Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29

Merck & Co., Inc. $MRK Stock Sold by Carolina Wealth Advisors LLC

Merck & Co., Inc. $MRK Stock Position Increased by Fifth Third Wealth Advisors LLC

AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

Merck CEO on melanoma vaccine results: The prescribing community will find results quite meaningful

Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

Merck & Co., Inc. $MRK Stock Position Increased by Brookstone Capital Management

Frequently Asked Questions About MRK

Beyond Keytruda: The Critical Pipeline Metrics to Watch in Merck's Q3 Results on Oct. 29

Merck & Co., Inc. $MRK Stock Sold by Carolina Wealth Advisors LLC

Merck & Co., Inc. $MRK Stock Position Increased by Fifth Third Wealth Advisors LLC

AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?

Merck CEO on melanoma vaccine results: The prescribing community will find results quite meaningful

Doctors call Moderna, Merck's cancer vaccine data a major advancement — even as stocks fall

Moderna Sinks 4% After 18% Plunge as Melanoma Vaccine Selloff Extends; Merck and Pfizer Slip

Merck & Co., Inc. $MRK Stock Position Increased by Brookstone Capital Management